Caribou Biosciences, Inc. quarterly report, Q1 FY2023

Caribou Biosciences, Inc. — Q1 2023 Form 10-Q

Reporting period: Three months ended March 31, 2023. Caribou is a clinical-stage genome-editing company developing allogeneic CAR-T and CAR-NK therapies. It has no products approved for sale and has generated no product-sales revenue.

Financial performance and liquidity

MetricQ1 2023Q1 2022 / comparison
Licensing and collaboration revenue$3.5 million$2.7 million; up $0.8 million (31%)
Research and development expense$25.7 million$13.9 million; up $11.8 million
General and administrative expense$8.9 million$9.6 million; down $0.7 million
Total operating expenses$34.6 million$23.5 million
Operating loss$31.1 million$20.9 million
Net loss; loss per share$28.0 million; $0.46$19.1 million; $0.32
Net cash used in operations$27.9 million$21.7 million
  • Other income was $3.1 million, including $2.8 million of other income, net, primarily reflecting higher interest income on marketable securities. The MSKCC success-payment liability fair-value gain was $0.3 million, versus $1.6 million in Q1 2022.
  • Cash, cash equivalents, and marketable securities totaled $291.0 million at March 31, 2023, down from $317.0 million at December 31, 2022. Total assets were $347.5 million; total liabilities were $69.2 million; stockholders’ equity was $278.3 million.
  • Cash and cash equivalents decreased $5.6 million during the quarter. Investing activities provided $20.7 million, mainly from marketable-security maturities and sales; financing activities provided $1.6 million, including ATM proceeds.
  • No conventional borrowings are identified in the provided balance sheet. Operating lease liabilities totaled $27.4 million. The filing reports no material ongoing financing commitments other than leases and certain license-agreement payments.
  • Gross profit and operating margins are not presented; the filing reports licensing and collaboration revenue and operating expenses separately.

Material changes and business developments

  • R&D expense rose substantially, primarily due to increased contract manufacturing and research activity, including work on CB-010 and CB-012, and higher personnel costs.
  • Revenue growth reflected higher AbbVie agreement revenue ($1.6 million versus $0.9 million) and increased revenue from other licensees. The three largest licensees represented 87.5% of accounts receivable and contract assets at quarter-end.
  • Caribou sold 168,635 shares through its ATM program by March 31, 2023, for $1.2 million gross proceeds ($1.0 million net); the program permits up to $100 million in gross sales. Its shelf registration statement permits offerings of up to $400 million, including the ATM capacity.
  • Potential future development, regulatory, and sales milestone payments under certain license and assignment agreements totaled approximately $161.2 million; payment depends on specified milestones and other agreement conditions.

Outlook, risks, and contingencies

  • Management expects existing cash, cash equivalents, and marketable securities to fund the current operating plan for at least 12 months from the financial-statement issuance date. The company expects continued substantial losses and says it may need additional capital; financing may be unavailable or require dilution or surrender of rights.
  • CB-010 is in the ANTLER Phase 1 trial; management planned a safety and efficacy update in the second half of 2023, including at least 15 dose-escalation patients with at least six months of follow-up. CB-011 is in the CaMMouflage Phase 1 trial, with dose-escalation updates expected as it advances. CB-012 remained in IND-enabling studies, with an IND submission planned for the second half of 2023. These are forward-looking plans, not reported outcomes.
  • Development, regulatory approval, clinical results, manufacturing capacity, third-party dependence, intellectual-property disputes, and future financing are material uncertainties. The company relies on external manufacturers and service providers and expects expenses to increase as programs advance.
  • Putative class actions allege misleading disclosures concerning CB-010’s therapeutic-effect durability and clinical and commercial prospects. One federal case was voluntarily dismissed in March 2023; a new federal case was filed in April, with a consolidation motion pending, and a related California state case was filed in March. Caribou says the claims are without merit and sought a stay of the state case.
  • Caribou reported no material indemnification claims or recorded related liabilities. It stated that no material risk-factor changes from its 2022 Form 10-K occurred during the quarter.

Important facts for investors to verify

  • Whether clinical updates for CB-010, CB-011, and the planned CB-012 IND submission occurred on the stated timelines, and what the resulting data show.
  • Cash burn, investment balances, and runway as R&D spending increases; the runway estimate is based on current operating assumptions.
  • Revenue concentration and the timing and durability of collaboration and license revenue, including deferred revenue and remaining performance obligations.
  • Potential dilution from ATM or other offerings, and the conditions and likelihood of contingent license milestone payments.
  • Progress and potential financial or operational effects of the CB-010-related securities lawsuits.